Physician profile
Dvinder Kaur
NPI 1285605238
$5,869.04
in general payments reported to CMS, 2019-2025
21 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $907 · 2021: $686 · 2022: $449 · 2023: $1,256 · 2024: $1,335 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,207.19 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Novo Nordisk INC | $767.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $503.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $414.34 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.99 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $244.37 | 2019-2023 | |
| Pfizer INC. | $230.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $228.78 | 2019-2023 | Verquvo, Steglatro |
| Intuity Medical INC | $221.86 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Esperion Therapeutics, INC. | $219.55 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $99.31 | 2021-2023 | Injectafer |
| Glaxosmithkline, LLC. | $98.09 | 2019-2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $93.39 | 2023-2025 | |
| Amgen INC. | $59.52 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $58.30 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $52.39 | 2022 | |
| Xeris Pharmaceuticals, INC. | $27.28 | 2021-2023 | Gvoke Hypopen |
| Bavarian Nordic A/S | $17.12 | 2025 | Vivotif |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2021 | |
| Althera Pharmaceuticals LLC | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dvinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.